Canagliflozin (CGZ)

Canagliflozin is a drug for the treatment of type 2 diabetes. Canagliflozin is an antidiabetic drug used to improve glycemic control in patients with type 2 diabetes. In clinical trials, canagliflozin produced a dose-dependent reduction in Hb1ac of 0.6 to 0.9 greater than that obtained with placebo when administered as monotherapy, in combination with metformin, or in combination with metformin and a sulfonylurea. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Canagliflozin is less effective in patients with moderate renal failure and probably ineffective in severe renal failure and type 1 diabetes. Canagliflozin increased (generally mild) urinary tract infections, genital mycotic infections, thirst, LDL cholesterol, and was associated with increased urination and episodes of hypotension.